Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6802704 | 0.98 | ALDH1A1 (0.37) | ALDH1A1EGLN1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6796958 | 0.85 | MAPT (0.44) | ALDH1A1EGLN1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6797275 | 0.85 | MAPT (0.44) | ALDH1A1EGLN1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL6796962 | 0.85 | MAPT (0.44) | ALDH1A1EGLN1CYP3A4CYP2D6CYP1A2 | |
| SCHEMBL5014969 | 0.77 | SLC22A6 (0.41) | ALDH1A1EGLN1CYP1A2ADRB2ADRB1 | |
| SCHEMBL8982365 | 0.77 | CYP2C19 (0.45) | ALDH1A1CYP3A4CYP2D6CYP1A2MAPT | |
| SCHEMBL986003 | 0.76 | PTPN1 (0.40) | FAAHFFAR4FFAR1 | |
| SCHEMBL6695805 | 0.75 | GABRR1 (0.37) | ALDH1A1CYP2D6CYP1A2TSHR | |
| SCHEMBL9169806 | 0.74 | SLC22A6 (0.52) | ALDH1A1MAPT | |
| SCHEMBL2553608 | 0.74 | MME (0.37) | ALDH1A1EGLN1CYP2D6FAAHMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315720-B1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-07-06 | — | — | EP | disclosed |
| US-6740651-B2 | TREATING PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-05-25 | — | — | US | disclosed |
| EP-1315720-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma KG (DE) | 2003-06-04 | — | — | EP | disclosed |
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-22 | — | — | US | disclosed |
| WO-2002018376-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115675-A1 | Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases | MAP3K1, MAP3K20, MAP3K19 | ALDH1A1 2059/4885EGLN1 982/4885CYP3A4 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.